Elanco Animal Health Incorporated Long-Term Debt, Maturity, after Year Five
Elanco Animal Health Incorporated (ELAN) had Long-Term Debt, Maturity, after Year Five of $1.86 billion as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2026-02-24
- 2025-12-31: Long-Term Debt, Maturity, after Year Five $1.86B.
- 2024-12-31: Long-Term Debt, Maturity, after Year Five $332.00M.
- 2023-12-31: Long-Term Debt, Maturity, after Year Five $235.00M.
- 2022-12-31: Long-Term Debt, Maturity, after Year Five $1.46B.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2025-12-31 | $1.86B 10-K · filed 2026-02-24 |
| 2024-12-31 | $332.00M 10-K · filed 2025-02-25 |
| 2023-12-31 | $235.00M 10-K · filed 2024-02-26 |
| 2022-12-31 | $1.46B 10-K · filed 2023-03-01 |
| 2021-12-31 | $5.06B 10-K · filed 2022-02-28 |
| 2020-12-31 | $4.70B 10-K · filed 2021-03-01 |
| 2020-09-30 | $4.71B 10-Q · filed 2020-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |